Marc Nash - 16 Nov 2023 Form 4 Insider Report for Outset Medical, Inc. (OM)

Role: SVP Operations and R&D
Signature: By: John L Brottem For: Marc Nash
Issuer symbol: OM
Transactions as of: 16 Nov 2023
Net transactions value: -$2,675
Form type: 4
Filing time: 17 Nov 2023, 16:15:48 UTC
Previous filing: 17 Aug 2023
Next filing: 17 Jan 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OM	Common Stock	Sale	$2,675	-562	-1.2%	$4.76	44,757	16 Nov 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of an aggregate of 1,484 shares of Common Stock underlying RSUs granted to the reporting person on March 8, 2021, March 15, 2021, and March 15, 2022. This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2	Includes 321 share of Common Stock acquired pursuant to the Outset Medical, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the purchase period of March 1, 2023 to August 31, 2023. This transaction is exempt from Rule 16b-3(c).

Content

Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of an aggregate of 1,484 shares of Common Stock underlying RSUs granted to the reporting person on March 8, 2021, March 15, 2021, and March 15, 2022. This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

Includes 321 share of Common Stock acquired pursuant to the Outset Medical, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the purchase period of March 1, 2023 to August 31, 2023. This transaction is exempt from Rule 16b-3(c).